Skip to main content
. 2010 Sep 15;42(10):721–730. doi: 10.3858/emm.2010.42.10.072

Figure 4.

Figure 4

Treatment with a non-specific NOS inhibitor (L-NAME), but not with an eNOS inhibitor (AP-CAV), inhibits lung inflammation induced by repeated allergen challenge with dsRNA. In all the experiments, the evaluation (n = 5 per group) was performed 48 h after the final allergen challenge; PBS, mice sensitized with OVA and then challenged with PBS; IC/OVA, mice sensitized and then challenged with OVA + poly(I:C); *, P < .05 compared to PBS; **, P < .05 compared to the other groups. (A) BAL cellularity after treatment with AP-CAV (1 mg/kg) and L-NAME (10 mg/kg) during allergen challenge. (B) Representative lung histologies (a, PBS; b, IC/OVA_sham; c, IC/OVA_AP-CAV; d, IC/OVA_L-NAME; H&E staining, original magnification × 200). (C) The levels of IP-10 and TGF-β1 (left panel) and TNF-α (right panel) in the BAL fluids.